



2060Intracameral phenylephrine and ketorolac
during cataract surgery to maintain
intraoperative mydriasis and reduce
postoperative ocular pain: Integrated results
from 2 pivotal phase 3 studies
John A. Hovanesian, MD, John D. Sheppard, MD, William B. Trattler, MD, Johnny L. Gayton, MD,
Ranjan P. Malhotra, MD, David T. Schaaf, MD, Edmund Ng, PhD, Steven H. Dunn, MD015 Th
s is a
ativecoPURPOSE: To evaluate the efficacy and safety of phenylephrine 1.0%–ketorolac 0.3% (Omidria) for
maintenance of mydriasis during, and reduction of ocular pain after, cataract surgery.
SETTING: Twenty centers in the United States and the Netherlands.
DESIGN: Prospective randomized clinical trials.
METHODS: Patients having cataract surgery or refractive lens exchange were enrolled in 2 clinical
trials. Phenylephrine 1.0%–ketorolac 0.3% or placebo was added to irrigation solution and admin-
istered intracamerally during the procedure. Integrated analyses of primary and secondary end-
points were conducted.
RESULTS: The clinical trials comprised 808 patients (403 treatment and 405 placebo). Phenyleph-
rine 1.0%–ketorolac 0.3% was superior to placebo for the maintenance of mydriasis during, and
reduction of ocular pain following, cataract surgery. The mean area under the curve (AUC) change
from baseline in pupil diameter was 0.08 mm for treatment compared with 0.50 mm for placebo
(P < .0001). The mean AUC of ocular pain visual analog scale scores within 12 hours postoperatively
was 4.16 mm for the treatment group and 9.06 mm for the placebo group (P < .001). Results of all
secondary efficacy analyses demonstrated a significant treatment effect associated with phenyleph-
rine 1.0%–ketorolac 0.3%. Treatment-emergent adverse events were as expected for a population
having cataract surgery; no clinically significant differences in safety measures were observed
between treatment groups.
CONCLUSION: In this integrated analysis, phenylephrine 1.0%–ketorolac 0.3% administered intra-
camerally with irrigation solution during cataract surgery was safe and effective for maintaining
mydriasis during the procedure and reducing postoperative ocular pain.
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million cases to 24 million cases.A Collectively, overe Authors. Published by Elsevier Inc. on behalf of ASCRS and ESCRS.
n open access article under the CC BY-NC-ND license (http://
mmons.org/licenses/by-nc-nd/4.0/).10% of ambulatory surgery procedures involve the
extraction of a lens or insertion of a prosthetic lens.1
As an age-related condition, the incidence of cataracthttp://dx.doi.org/10.1016/j.jcrs.2015.10.053
0886-3350
2061INTRACAMERAL PHENYLEPHRINE AND KETOROLACis expected to increase significantly over time2,A and,
accordingly, the number of cataract extractions with
intraocular lens (IOL) replacement is also expected to
increase. Several technical improvements in cataract
surgery have been made over the past decade, result-
ing in shorter procedures and faster recovery times.3,4
However, improvements in perioperative treatments
to facilitate these procedures and improve postopera-
tive outcomes are still needed.
In the United States, the majority of cataracts are
removed with extracapsular extraction by phacoemul-
sification.B Surgical steps and techniques for routine
uncomplicated cases are well documented and, in gen-
eral, are performed in a standardized manner across
ophthalmic surgeons. However, the use of pharmaco-
logic agents, including mydriatic agents, among sur-
geons is not well standardized. With the projected
growth in these procedures, more attention should
be paid to the use of these agents to prevent subjecting
patients to unnecessary risk. Combination intracam-
eral mydriatic agents are now commonly adminis-
tered during cataract surgery instead of traditional
preoperative topical drops.5–7 Although reported to
be effective for achieving and maintaining mydriasis
with limited safety issues, these conventionally
administered combinations of agents are not approved
by the U.S. Food and Drug Administration (FDA) and
therefore must be compounded by local pharmacies or
surgery staff, a practice associated with considerable
variations in potency and quality of the drug pro-
duct.C In response, the U.S. Congress enacted the
Drug Quality and Security Act, signed into law inSubmitted: October 14, 2014.
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J CATARACT REFRACT SURG -November 2013. While pharmacy compounding for
individual patients with a prescription is still allowed
under Section 503A, this act created a new section,
Section 503B, defining a new category of compounder
called an “outsourcing facility” that can compound
medications in bulk only if specific requirements
are followed, including complying with Good
Manufacturing Practices (GMP) requirements, sub-
mission to FDA inspection, and registration of the
facility with the FDA.D
Phenylephrine 1.0%–ketorolac 0.3% (Omidria) is a
commercially available FDA-approved combination
drug product containing phenylephrine, an a1-
adrenergic receptor agonist, and ketorolac, a nonselec-
tive cyclooxygenase inhibitor, indicated for use during
cataract surgery or intraoperative lens replacement.
Phenylephrine 1.0%–ketorolac 0.3% represents a new
treatment option for ophthalmic surgeons to address
2 common concerns associated with these procedures:
intraoperative miosis and postoperative ocular pain.
The safety and efficacy of phenylephrine 1.0%–ketoro-
lac 0.3% have been established in several nonclinical
and controlled clinical studies. Following addition to
irrigation solution, administration of phenylephrine
1.0%–ketorolac 0.3% requires no modification to the
surgical technique and, unlike products from unregis-
tered compounding facilities, offers the added benefit
of uniform production under GMP. Here, we present
integrated safety and efficacy results from 2 phase 3
pivotal clinical studies performed to support regulato-
ry approval of the drug product.
PATIENTS AND METHODS
Two pivotal multicenter randomized parallel-group double-
masked placebo controlled phase 3 studies (referred to as
study 1 and study 2) were performed to support the use of
phenylephrine 1.0%–ketorolac 0.3% for maintaining intrao-
perative mydriasis, preventing intraoperative miosis, and
reducing early postoperative ocular pain associated with
cataract surgery. Twenty sites in the U. S. and Netherlands
enrolled patients in these studies. All sites received approval
from an institutional review board or ethics committee, and
informed consent was obtained from all participating
patients. The studies were conducted in accordance with
the ethical principles described in the Declaration of Helsinki
(2008), theCode of Federal Regulations, and the International
Conference on Harmonisation, including maintenance of
patient confidentiality and compliance with the U. S. Health
Insurance Portability and Accountability Act. Both studies
are registered at ClinicalTrials.gov as NCT01454063E (study
1) and NCT01579565F (study 2). Because these 2 studies
were of similar design with consistent results, a pooled anal-
ysis of the study results is presented.Patients and Study DesignThe designs of the 2 studies were identical with the excep-
tion of a few details as specified, enabling integration of data
for pooled analyses. In particular, primary efficacy measuresVOL 41, OCTOBER 2015
2062 INTRACAMERAL PHENYLEPHRINE AND KETOROLACand safety evaluations were collected and evaluated in the
same manner. Both studies enrolled patients who were
18 years or older who were scheduled to have cataract
extraction and lens replacement or refractive lens exchange
and who had a baseline intraocular pressure (IOP) of 5 to
22 mm Hg.
Patients with concurrent clinically significant systemic
disease; connective tissue disease; abnormal blood pressure
at screening; narrow-angle or unstable glaucoma or treat-
ment with prostaglandins; history of iritis or trauma with
iris damage in the study eye; pseudoexfoliations; uncon-
trolled chronic eye disease or active corneal pathology or
scarring; recent surgery in the study eye (non-laser surgery
within 3 months or laser surgery within 30 days prior to
study surgery); hypersensitivity to required study medica-
tion; use of preoperative phenylephrine, nonsteroidal antiin-
flammatory drugs (NSAIDs), corticosteroids (topical,
inhaled, or oral), or ocular mast stabilizers within 7 days
before study surgery; use of monoamine oxidase inhibitors
within 21 days before surgery; use of depot corticosteroids
within 30 days prior to surgery; use of pilocarpine within
6 months prior to surgery; or history of a1-adrenergic antag-
onist use were excluded from the studies. In study 2, preop-
erative use of cyclosporine was also a key exclusion criterion.
In both studies, only 1 study eye per patient was evaluated.
Screening evaluations were performed up to 28 days
before the day of surgery. Upon meeting eligibility require-
ments, patients were randomized to phenylephrine 1.0%–
ketorolac 0.3% or placebo (1:1; stratified within each site by
cataract nuclear grade from the Lens Opacities Classification
System II8). Treatment assignment was masked to all
patients, investigators, and study-related personnel. Preop-
erative treatments were standardized for all patients and
included moxifloxacin 0.5% (Vigamox) treatment for at least
3 days before surgery, mydriatic treatment with topical
phenylephrine HCl 2.5% plus tropicamide 1.0% 3 times in
the 30 minutes before surgery, and lidocaine or tetracaine
for local anesthesia on the day of surgery. A single adminis-
tration of the study drug (483 mM phenylephrine and 89 mM
ketorolac formulated in 20 mM sodium citrate buffer) or pla-
cebo (20 mM sodium citrate buffer) was added to a balanced
salt solution (500 mL) and administered intracamerally as
part of the standard irrigation solution during the procedure
(final approximate concentrations of 0.01% [w/v] phenyl-
ephrine and 0.003% [w/v] ketorolac). Postoperative evalua-
tions were conducted for up to 14 days (study 1) or 90 days
(study 2); integrated safety analyses were limited to data
collected up to 14 days after surgery.EndpointsTwo co-primary endpoints were prespecified for the inte-
grated analyses: (1) intraoperative pupil diameter during
surgery and (2) ocular pain during the early postoperative
period following surgery. Each patient's surgical procedure
was video-recorded, and change in pupil diameter was
measured at 1-minute intervals from the time of incision
(surgical baseline) until wound closure (surgical end) by a
single masked central reader. Postoperative ocular pain
was measured using a patient-assessed 100 mm visual
analog scale (VAS) 2, 4, 6, 8, and 10 to 12 hours after surgery
and at 2, 7, and 14 days.
Key secondary endpoints included pupil diameter less
than 6.0 mm at end of cortical cleanup, pupil diameter less
than 6.0 mm at any time during surgery, moderate to severeJ CATARACT REFRACT SURG -ocular pain (VASR40) at any time point assessed within the
first 12 postoperative hours, and no ocular pain (VASZ 0) at
all timepoints assessed within the first 12 postoperative
hours. Post hoc secondary analyses included categorization
of the patient's intraoperative pupil constriction and anal-
gesic use on the day of surgery.
Safety endpoints consisted of adverse events, serious
adverse events, and specific ophthalmologic safety mea-
sures, including corrected distance visual acuity assessed us-
ing the Early Treatment Diabetic Retinopathy Studymethod,
postoperative inflammation measured using the Summed
Ocular Inflammation Score, evaluation of IOP, and findings
from standard ophthalmologic examinations performed
throughout the course of the study.Statistical AnalysisEach study was performed independently. The sample
size calculations for the 2 studies were identical: A total of
400 patients (200 patients per treatment arm) in each study
provided 99% power to detect a difference of 0.6 mm
(standard deviation [SD] 0.7 mm) in the mean area under
the curve (AUC) pupil diameter change from baseline and
96% power to detect a difference of 5.0 mm (SD 13.3 mm)
in the mean AUC of ocular pain VAS during the first 12 post-
operative hours using a 2-sided t test with a equal to 0.05.
The mean AUC pupil diameter change from baseline dur-
ing surgerywas calculated as follows: (1) the trapezoidal rule
was used to calculate the AUC of the pupil diameter from
surgical baseline towound closure, (2) the result was divided
by time of the last pupil diameter value to obtain the mean
AUC, and (3) the baseline pupil diameter was subtracted
from the mean AUC. The AUC of ocular pain VAS during
the first 10 to 12 postoperative hours was also calculated
using the trapezoidal rule with the mean AUC defined as
the AUC divided by the number of hours from the first
VAS score to the last VAS score within this timeframe. For
both primary endpoints, a generalized Cochran-Mantel-
Haenzel test stratified by randomization strata was used to
compare the 2 treatment arms for the 2 studies combined.9
Treatment comparisons for all secondary efficacy analyses
presented were performed using the chi-square test or Fisher
exact test if the frequency in a category was less than 5. All
statistical analyses were performed using SAS software
(version 9.3, SAS Institute, Inc.).RESULTSPatient Characteristics and DispositionPatients were enrolled from October 7, 2011, to
January 17, 2012 (study 1), and from April 4, 2012, to
September 26, 2012 (study 2). Among a total of 821
patients randomized, 808 were treated with phenyl-
ephrine 1.0%–ketorolac 0.3% (n Z 403) or placebo
(n Z 405). Primary reasons for not receiving study
drug included occurrence of adverse event prior to
surgery and withdrawal of consent (Figure 1). Preop-
erative adverse events that excluded patients from
study drug and further participation in the study
included worsening/exacerbation of hypertension
(nZ 2), atrial fibrillation, elevated blood pressure, sec-
ondary leg cellulitis, and worsening confusion (nZ 1VOL 41, OCTOBER 2015
Figure 1. Patient disposition flow
diagram (consolidated standards of
reporting trials) (Study Treatment
Z phenylephrine 1.0%–ketorolac
0.3%).
2063INTRACAMERAL PHENYLEPHRINE AND KETOROLACeach). Five hundred eighty-one patients (72%) were
65 years of age or older, and all but 7 patients had cata-
ract extraction surgery (Table 1). Patient demographic
and baseline characteristics were similar between the
treatment groups.EfficacyMaintenance of Mydriasis Phenylephrine 1.0%–ketoro-
lac 0.3% was better than the placebo in maintaining
mydriasis during cataract surgery. Among 759
patients with usable video images for determination
of pupil diameter, the mean AUC change from base-
line in pupil diameter was 0.08 mm in the treatment
group (n Z 379) and 0.50 mm in the placebo
group (n Z 380), and the Cochran-Mantel-Haenzel–
weighted mean difference (treatment–placebo)J CATARACT REFRACT SURG -(standard error) was 0.58 mm (0.04) (95% confidence
interval [CI], 0.51–0.65; P ! .0001). After initiation of
surgery, baseline pupil diameter was maintained
with phenylephrine 1.0%–ketorolac 0.3% treatment,
while progressive miosis was observed with placebo
treatment (Figure 2). Although Figure 2 shows data
points up to 30 minutes from initiation of surgery, 9
(1.1%) of the 808 patients had surgery that lasted
beyond 25 minutes.
Results of secondary efficacy analyses evaluating
the incidence of patients with pupil diameter less
than 6.0 mm at completion of cortical cleanup and at
any time during surgery also favored phenylephrine
1.0%–ketorolac 0.3% treatment (Table 2). The propor-
tions of patients with pupil diameter less than
6.0 mm at the time of cortical cleanup completion, pu-
pil diameter less than 6.0 mm at any time duringVOL 41, OCTOBER 2015
Table 1. Demographic and baseline characteristics.
Characteristic







MeanG SD 68G 10.2 69G 9.4
Median 69.0 69.0
Min, Max 26, 90 31, 88
Age group (y), n (%)
18–64 116 (28.6) 111 (27.5)
R65 289 (71.4) 292 (72.5)
R75 105 (25.9) 114 (28.3)
Sex, n (%)
Male 168 (41.5) 167 (41.4)
Female 237 (58.5) 236 (58.6)
Race, n (%)
American Indian or Alaska
Native
1 (0.2) 2 (0.5)
Asian 37 (9.1) 28 (6.9)
Black or African American 54 (13.3) 40 (9.9)
Native Hawaiian or other
Pacific Islander
0 1 (0.2)
White 313 (77.3) 330 (81.9)
Other 0 2 (0.5)
LOCS II grade, n (%)
Low (N0, N1) 331 (81.7) 324 (80.4)
High (N2, N3) 74 (18.3) 79 (19.6)
Iris color, n (%)
Black 1 (0.2) 0
Blue 108 (26.7) 122 (30.3)
Brown 212 (52.3) 214 (53.1)
Green 6 (1.5) 3 (0.7)
Gray 32 (7.9) 26 (6.5)
Other 45 (11.1) 38 (9.4)
Hazel 1 (0.2) 0
Surgery received, n (%)
Refractive lens exchange 5 (1.2) 2 (0.5)
Cataract extraction and
lens replacement
400 (98.8) 401 (99.5)
LOCSZ Lens Opacities Classification System; Study TreatmentZ phen-
ylephrine 1.0%–ketorolac 0.3%
Figure 2.Mean (GSE) change from baseline in mean pupil diameter
over time to the end of surgery. Pupil diameters weremeasured at 1-
minute intervals from baseline to the end of the procedure and at the
end of cortical cleanup from a video recording of the patient's sur-
gery (Study TreatmentZ phenylephrine 1.0%–ketorolac 0.3%).
2064 INTRACAMERAL PHENYLEPHRINE AND KETOROLACsurgery, and degree of intraoperative pupillary
constriction of equal to or more than 2.5 mm were all
significantly lower among treated patients than pla-
cebo patients (P! .0001 for each endpoint). Consider-
ably fewer treated patients than placebo patients
experienced intraoperative pupil constriction greater
than 1.0 mm (Figure 3).
Reduction in Early Postoperative Ocular Pain Treatment
with phenylephrine 1.0%–ketorolac 0.3% was associ-
atedwith a significant reduction in early postoperative
ocular pain compared to placebo, an outcome likely
attributable both to the effect of ketorolac as anNSAIDJ CATARACT REFRACT SURG -and to maintenance of a larger intraoperative pupil
diameter facilitating less trauma to the iris during sur-
gery. Ocular pain VAS scores (using a 100 mm scale)
during the first 12 hours postoperatively were more
than 50% lower in the treatment group (mean
AUCZ 4.16 mm, nZ 403) than in the placebo group
(mean AUC Z 9.06 mm; n Z 403). The Cochran-
Mantel-Haenzel–weighted mean difference (treat-
ment–placebo) (standard error) in AUC of ocular
pain scores was 4.89 mm (0.80) (95% CI, 6.46 to
3.31; P ! .001). The mean VAS scores were lower
among patients treated with phenylephrine 1.0%–
ketorolac 0.3% at each postoperative timepoint
(Figure 4). The proportion of patients who were ocular
pain–free (VAS Z 0) at all postoperative timepoints
was significantly higher in the treatment group than
in the placebo group (104/403 [25.8%] versus 69/403
[17.1%], respectively; PZ .0027) (Table 2), and the pro-
portion of patients with moderate to severe ocular pain
(VASR40) at any postoperative timepoint was signif-
icantly lower for phenylephrine 1.0%–ketorolac 0.3%
than for placebo (29/403 [7.2%] versus 57/403
[14.1%], respectively; PZ .0014). Notably, in addition
to lower VAS pain scores in the treatment group, use
of oral analgesics on the day of surgery was also signif-
icantly lower among patients treated with phenyleph-
rine 1.0%–ketorolac 0.3% than in patients receiving
placebo (99/403 [24.6%] versus 142/405 [35.1%],
respectively; PZ .0010).SafetyOf the 808 patients (403 treatment group, 405 pla-
cebo group) included in the pooled safety analyses,
513 (63.5%) experienced at least 1 treatment-VOL 41, OCTOBER 2015
Table 2. Supportive efficacy endpoints.
Endpoint Placebo (nZ 405) Study Treatment (nZ 403)
Pupil diameter endpoints, n/N (%)
Subjects with!6.0 mm at cortical clean-up 87/380 (22.9) 15/379 (4.0)
P value* !.0001
Subjects with!6.5 mm at any time during surgery 161/380 (42.4) 37/379 (9.8)
P value* !.0001
Subjects withR2.5 mm of pupillary constriction at any time during surgery† 103/380 (27.1) 8/379 (2.1)
P value* !.0001
Ocular pain endpoints, n/N (%)
Subjects pain-free (VASZ 0) at all timepointsz 69/403 (17.1) 104/403 (25.8)
P value* .0027
Subjects with moderate to severe pain (VASR40) at any timepoint 57/403 (14.1) 29/403 (7.2)
P value* .0014
Analgesic use on day of surgeryx 142/405 (35.1) 99/403 (24.6)
P value* .0010
Study TreatmentZ phenylephrine 1.0%–ketorolac 0.3%
*Chi-square test
†Maximum decrease in pupil diameter from baseline during surgery
zSubjects with missing VAS during 12 hours postoperatively are considered as not being pain-free
xMost commonly administered analgesics included paracetamol and fentanyl
2065INTRACAMERAL PHENYLEPHRINE AND KETOROLACemergent adverse event (Table 3). The proportion of
patients reporting treatment-emergent adverse events
was slightly lower among patients receiving phenyl-
ephrine 1.0%–ketorolac 0.3% than those receiving
placebo. The majority of treatment-emergent adverse
events were mild or moderate in severity. Only 1
serious adverse event was reported in the 2 studies.
This event (death caused by electrocution in a work-
place accident, deemed unrelated to study drug) was
also the only event that resulted in premature discon-
tinuation from the studies.
The most frequently reported treatment-emergent
adverse event consisted of eye pain, eye inflamma-
tion anterior chamber inflammation, headache, IOPFigure 3. Maximum intraoperative pupil constriction (Study Z
phenylephrine 1.0%–ketorolac 0.3%).
J CATARACT REFRACT SURG -increase, posterior capsule opacification, ocular dis-
comfort, photophobia, corneal edema, blurred vision,
conjunctival hyperemia, and foreign-body sensation
in the eyes. These events were reported by similar pro-
portions of patients in each treatment group with the
exception of eye pain, headache, ocular discomfort,
photophobia, and blurred vision, which were experi-
enced by slightly more (O1.0% difference between
treatment groups) placebo patients than phenyleph-
rine 1.0%–ketorolac 0.3% patients. Increased IOP was
the only common treatment-emergent adverse event
occurring in a slightly greater proportion (O1.0%
difference) of phenylephrine 1.0%–ketorolac 0.3%
treated patients.Figure 4. Mean ocular pain VAS scores during the early postopera-
tive period (StudyZ phenylephrine 1.0%–ketorolac 0.3%).
VOL 41, OCTOBER 2015
Table 3. Adverse events occurring in more than 2% of subjects overall.
Preferred Term Placebo (nZ 405), n (%) Study Treatment (nZ 403), n (%) Total (nZ 808), n (%)
Any event 271 (66.9) 242 (60.0) 513 (63.5)
Eye pain 162 (40.0) 122 (30.3) 284 (35.1)
Eye inflammation 62 (15.3) 63 (15.6) 125 (15.5)
Anterior chamber inflammation 34 (8.4) 36 (8.9) 70 (8.7)
Headache 38 (9.4) 26 (6.5) 64 (7.9)
Intraocular pressure increased 14 (3.5) 19 (4.7) 33 (4.1)
Posterior capsule opacification 15 (3.7) 18 (4.5) 33 (4.1)
Ocular discomfort 21 (5.2) 12 (3.0) 33 (4.1)
Photophobia 20 (4.9) 12 (3.0) 32 (4.0)
Corneal edema 12 (3.0) 11 (2.7) 23 (2.8)
Vision blurred 17 (4.2) 5 (1.2) 22 (2.7)
Conjunctival hyperemia 10 (2.5) 11 (2.7) 21 (2.6)
Foreign body sensation in eyes 10 (2.5) 8 (2.0) 18 (2.2)
Study TreatmentZ phenylephrine 1.0%–ketorolac 0.3%
2066 INTRACAMERAL PHENYLEPHRINE AND KETOROLACSevere treatment-emergent adverse events were
experienced by 18 patients (13 placebo patients
[3.2%] and 5 treatment patients [1.2%]). Except for
the event of accidental electrocution experienced by
a patient treated with phenylephrine 1.0%–ketorolac
0.3%, all severe treatment-emergent adverse events
consisted of eye disorders, including eye inflammation
(nZ 11), anterior chamber inflammation (nZ 2), and
conjunctival edema, corneal edema, conjunctival hy-
peremia, eye pain, and photophobia (nZ 1 each). Of
note, all severe treatment-emergent adverse events
considered to be related to study treatment occurred
among patients receiving placebo. These events
included 2 instances of anterior chamber inflammation
and events of corneal edema, eye pain, photophobia,
eye inflammation, and conjunctival hyperemia.
Increased IOP was observed for several patients in
both treatment groups following surgery. By day 2,
increases compared to baseline were less notable;
however, the abnormality persisted in some patients
through the end of the study. No notable treatment-
emergent adverse events were reported in these
patients, and no differences in the proportions of pa-
tients with increased IOP were observed between the
2 treatment groups on each evaluation day. In addi-
tion, no differences between treatment groups were
observed for any other serial assessments of safety
(ie, vital signs or ophthalmologic examinations).
DISCUSSION
Maintenance of an adequate operative field during
cataract surgery continues to be a concern for many
ophthalmic surgeons. Traditional topical preopera-
tive mydriatic agents such as phenylephrine, tropica-
mide, and cyclopentolate10 are beneficial in most
cases; however, intraoperative miosis due to theJ CATARACT REFRACT SURG -release of prostaglandins in response to the surgical
trauma may still occur.11 Preoperative use of topical
NSAIDs has been shown to improve maintenance of
intraoperative pupil diameter and reduce postopera-
tive discomfort.12 In a recent study,12 preoperative
administration of ketorolac 0.4%, prednisolone 1%,
or nepafenac 0.1% was superior to placebo in main-
taining intraoperative mydriasis. However, as with
any topical medication, these may be “washed out”
with the irrigation solution during the cataract proce-
dure, limiting the ability to inhibit the inflammatory
cascade during the procedure.
The use of intracameral agents, particularly lido-
caine with or without epinephrine or phenylephrine,
is another approach commonly used to help maintain
visualization during cataract surgery.13,14 In a small
study of 57 patients having phacoemulsification with
IOL implantation,13 intracameral injection of lidocaine
1.0% alone resulted in significantly greater mean pupil
diameters compared with pupil diameters following
administration of topical mydriatics (cyclopentolate
1.0% and phenylephrine 5.0%) The combination of
lidocaine 0.75% and epinephrine 0.025% administered
intracamerally has also been shown to result in effec-
tive pupil dilation.14
Although several combinations of intracameral
agents are being used during cataract replacement
procedures, the only FDA-approved product that con-
tains more than 1 agent for this use is Omidria. Across
the unapproved products, no consistent approach in
their use has been adopted among surgeons.5–7 More-
over, there have been a number of well-publicized
cases of improperly compounded ophthalmologic
solutions leading to infection and, in rare cases, blind-
ness. This lack of consistency is concerning as it may
introduce additional safety risks for patients havingVOL 41, OCTOBER 2015
2067INTRACAMERAL PHENYLEPHRINE AND KETOROLACcataract surgery. Although many intraoperative
devices such as the Beehler pupil dilator (Moria SA)
and Malyugin ring (Microsurgical Technology) are
available for surgical situations involving small
pupils, use of these devices complicates and prolongs
the procedure, traumatizes the iris thereby increasing
postoperative inflammation, and may negatively
impact postsurgical outcomes.15
Surgeons' perceptions of postoperative pain and
approach to pain management following cataract sur-
gery have also been shown to be inconsistent. A review
of published information for the incidence, prevalence,
and management of pain after cataract surgery with
phacoemulsification conducted by Porela-Tiihonen
et al.16 revealed highly variable results. Notably, acute
postoperative pain (defined as ophthalmologic pain
experienced during the first postoperative hours prior
to discharge from the surgical center) was only evalu-
ated in 5 of 21 studies identified with pain as an
outcome measure and ranged from an incidence of
6% to 95% for “any pain” and 1% to 35% for “moderate
to severe pain.” The study authors subsequently per-
formed a prospective study of postoperative pain after
cataract surgery that showed moderate or severe pain
was indeed relatively common, with 27% of patients
experiencing this degree of painwithin 4 hours postop-
eratively.17 This suggests thatmore attention should be
paid to the occurrence of postoperative pain and pain
management related to these procedures.
Omidria is a new treatment approved by the FDA
in May 2014 for use during cataract surgery or intra-
operative lens replacement. It contains both phenyl-
ephrine and ketorolac in a combination that has
been specifically formulated for use in ophthalmic
irrigation solution used during these procedures.
Phenylephrine, an a1-adrenergic receptor agonist,
acts as a mydriatic agent when administered to the
eye by contracting the radial muscle of the iris.18
Ketorolac, an NSAID, inhibits both proinflammatory
cyclooxygenase enzymes (COX-1 and COX-2),
thereby inhibiting synthesis of prostaglandins result-
ing from surgical trauma and reducing postoperative
pain.19 The inhibition of prostaglandin production by
ketorolac has also been shown to prevent surgically
induced miosis. The introduction of phenylephrine
1.0%–ketorolac 0.3% as a treatment option to simulta-
neously address 2 notable concerns associated with
cataract surgerydintraoperative miosis and post-
operative paindrepresents a positive step toward
standardizing treatment during this commonly per-
formed procedure.
The integrated results of the 2 pivotal phase 3 studies
presented herein demonstrate the superiority of phen-
ylephrine 1.0%–ketorolac 0.3% over placebo inJ CATARACT REFRACT SURG -maintaining pupil diameter during, and reducing
ocular pain following, cataract extraction with lens
replacement or refractive lens exchange procedures,
even though all patients received standard preopera-
tive topicalmydriatics and anesthetics. The efficacy an-
alyses were robust; AUC analyses of the co-primary
endpoints for the integrated analysis, performed to
show the aggregate effect of phenylephrine 1.0%–
ketorolac 0.3% on pupil diameter during surgery and
early postoperative pain, and all secondary efficacy an-
alyses were supportive. Furthermore, phenylephrine
1.0%–ketorolac 0.3% was not associated with any
newor additional toxicities compared toplacebo.Com-
mon adverse events and safety findings (eg, increased
IOP) observed in clinical studies of phenylephrine
1.0%–ketorolac 0.3% performed to date are consistent
with events commonly reported among patients hav-
ing these procedures, and no clinically significant dif-
ferences between treatment groups were observed.
Of the 808 patients included in the phase 3 studies of
Omidria presented here, 581 (72%) were at least
65 years of age or older. With age-related cataracts as
the most common form of this disease,A many patients
having cataract surgery may also have associated co-
morbidities, which could complicate the treatment
and management of cataracts in the future. The
controlled clinical settings in which phenylephrine
1.0%–ketorolac 0.3% was evaluated will enable addi-
tional subgroup safety and efficacy analyses in these
special populations and possibly lead to further
studies.VOWHAT WAS KNOWN
 Topical and intracameral ocular agents are commonly
used to achieve and/or maintain mydriasis to enable suc-
cessful cataract surgery.
 Topical agents are also commonly used preoperatively
and postoperatively to reduce pain, inflammation, and in-
fections associated with these procedures.WHAT THIS PAPER ADDS
 Phenylephrine 1.0%–ketorolac 0.3% when added to irri-
gation solution and delivered intracamerally during cata-
ract surgery was better than placebo in maintaining
pupil diameter and preventing miosis throughout the
procedure.
 Patients who received phenylephrine 1.0%–ketorolac
0.3% during cataract surgery experienced less pain
than placebo patients during the early postoperative
period.L 41, OCTOBER 2015
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